DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

α-Neoendorphin, actions and
selectivities of, 485t
Neomycin, 1518
adverse effects and side effects of,
1817
prophylaxis, for superficial
infections, 1817
Neoplastic diseases, chemotherapy for,
1668t–1670t
NEOPROFEN (ibuprofen), 988
NEOSPORIN ORIGINAL OINTMENT, 1817
Neostigmine
and ACh, 241f
and AChE, 241–242
cholinergic receptors and, 207t
structure of, 243f
for urinary bladder atony, 250
Nepafenac, for ophthalmic use, 1789
Nephron
anatomy of, 671, 672f
function, 673–674
nomenclature for, 671, 672f
subdivisions of, 671, 672f, 673
tubuloglomerular feedback, 673
Nephrotic syndrome
diuretics for, 699–701
and dyslipidemia, 890t
Nernst equation, 816
Nerve block anesthesia, 576–577
“Nerve gases,” 243
Nervi erigentes, 175
Nervous system
autonomic
acetylcholine in, 172, 177f
anatomy of, 171–181, 173f
co-transmission in, 213–214
effector organ responses to, 176
functions of, 171–181
somatic vs., 171
central
action of drugs in, 390–393
adrenocorticosteroids and, 1221
amino acids in, 376
amphetamines and, 298
angiotensin II and, 729
aspartate in, 379–380
barbiturates and, 469–472
benzodiazepines and, 460
beta-adrenergic receptor
antagonists and, 317
cannabinoids in, 388
carbon dioxide and, 562
cell signaling in, 373–376
depressants, 390–392, 654–657
distribution of drugs and, 25
dopamine and, 355–356
Nervous system, central (Cont.):
drug discovery, 393
drug interactions, 392–393
eicosanoids and, 951
epinephrine and, 285
ethanol and, 633–635
fentanyl and, 507
GABA in, 376–379
glutamate in, 379–380
glycine in, 379
histamine and, 384–388, 915
H 1
receptor antagonists and,
919–920
integrative chemical
communication in, 366–371
lipid mediators in, 389–390
meperidine and, 503–505
methadone and, 508
muscarinic antagonists and, 230,
233–234
neuromuscular blocking agents
and, 261–262
neurotransmitter receptor-effector
coupling in, 371–372
nicotine and, 271
nitric oxide in, 390
organizational principles of,
363–366
plasticity of, 366
repair of, 366
serotonin and, 341–342
stimulants, 392
supportive cells in, 365
synaptic transmission in, 373–376
transmitter interactions, 393
vasopressin and, 708
endocrine system and, 210
enteric, 175, 1323–1324
parasympathetic, 171, 174–175
peripheral, nicotine and, 271
sympathetic, 171, 172–174
Nesiritide, 696
NET. See Norepinephrine transporter
(NET)
Netherton’s syndrome, tacrolimus and,
1822
N-ethylmaleimide-sensitive fusion
protein (NSF), 199
Netilmicin, 1517
Neuroblastoma, drugs for, 1668t–1670t
Neurodegenerative disorders
cellular mechanisms of, 610–611
environmental triggers and, 610
genetics of, 610
neuroprotective strategies in,
609–619
selective neuronal vulnerability in,
609–619
Neuroleptic malignant syndrome
antidote for, 86t
in antipsychotic drug therapy, 437t
Neuroleptics, neurological side effects
of, 437t
Neuromuscular blockade,
measurement of, 265
Neuromuscular blocking agents,
258–268
as anesthetic adjuncts, 554
classification of, 264t
competitive vs. depolarizing, 267t
dosing ranges for, 265t
malignant hyperthermia and, 268
respiratory paralysis with, 268
structural formulas of, 259f
Neuromuscular junction,
anticholinesterase agents
and, 246
Neuronal nicotinic receptor
composition, 256–258
Neuronal-type nicotinic receptors, 190,
191t
Neuropeptides, as pruritogens, 1815
Neuropeptide Y, 182
in autonomic co-transmission,
213–214
storage, 197f
synthesis, 197f
Neuropeptide Y (NPY), and
vasopressin secretion, 704
Neurotoxicity
of alkylating agents, 1682
of organophosphates, 249–250
Neurotransmission, 181–210
adrenergic, 194–210
axonal conduction in, 182–183
cholinergic, 185–189
conduction in, 182
evidence for, 181–182
excitatory, 183f
ganglionic, 269–270
historical aspects of, 181
inhibitory, 183f
junctional transmission in,
183–185
purines in, 214
steps involved in, 182–185
transmission vs. conduction in, 182
Neurotransmitters
central, 376–390
destruction of, 185
interference with, 212
dissipation of, 185
2051
INDEX